NIH Locks Down Blood and Tissue from Sneaky Foreign Spies
Published Date: 12/12/2025
Notice
Summary
The NIH now requires stronger security for human biospecimens funded by them to protect people and national safety. This affects researchers and labs handling these samples, with new rules effective since October 24, 2025. These changes help stop risky access by foreign countries and don’t add extra costs but do require careful handling.
Analyzed Economic Effects
5 provisions identified: 2 benefits, 3 costs, 0 mixed.
Applies to all NIH‑funded biospecimens
The policy applies to all human clinical and research biospecimens obtained from U.S. persons that are collected, obtained, stored, used, or distributed with any on-going or new NIH funding mechanism, regardless of NIH funding level. This rule became effective October 24, 2025 and covers biospecimens from U.S. persons whether or not they are identifiable.
Ban on sharing with countries of concern
Entities that hold NIH‑funded human biospecimens of U.S. persons are prohibited from directly or indirectly distributing those biospecimens to institutions or parties located in 'countries of concern' as determined under 28 CFR 202.601. The prohibition applies to biospecimen distribution unless one of the policy's limited exceptions is met.
Limited exceptions allow some transfers
Biospecimens may be shared with countries of concern only in limited circumstances: (1) transactions required or authorized by Federal law or international agreements (including global health) or necessary for compliance with Federal law; (2) rare and compelling cases where needed capability/expertise exists only in that country and the individual consented; or (3) at the request of the individual for their diagnosis, prevention, or treatment and in compliance with applicable Federal laws. Any such sharing must meet these specified conditions.
Documentation and retention requirement
NIH requires entities that share or distribute biospecimens to countries of concern under an allowable exception to retain documentation of those transactions, including the quantity and content of material shared, and to provide that documentation to NIH upon request. Entities must keep these records for any sharing done under the policy's limited circumstances.
Exemption for already public/commercial cell lines
The policy does not apply to cell derivative products or cell lines derived from human biospecimens of U.S. persons that were commercially or publicly available prior to the policy's effective date of October 24, 2025. However, cell lines that had agreements to be made commercially or publicly available but were not yet available on or after the effective date remain covered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in